Advisors on Santhera–Nxera Agamree licensing agreement for Japan, South Korea, Australia and New Zealand

Orrick and Bär & Karrer advised Nxera, while Santhera Pharmaceuticals was represented by its in‑house legal team. SIX‑listed Santhera Pharmaceuticals has entered an exclusive licensing agreement with Nxera Pharma for the development, manufacturing and commercialisation of Agamree, a prescription medicine for the treatment of Duchenne muscular dystrophy (DMD), in Japan, South Korea, Australia and New Zealand. Under the agreement Nxera will provide Santhera with an upfront consideration of USD 40 million, consisting of USD 30 million in cash and a USD 10 million equity investment in Santhera. Nxera will pursue regulatory approval for Agamree in the licensed territories and will lead related commercial and manufacturing activities across those regions. Orrick represented client(s) Nxera with a team composed by: David Schulmann (led Orrick’s US‑based team). Bär & Karrer represented client(s) Nxera with a team composed by: Urs Kägi; Luca Jagmetti (led the Swiss side advising on the investment agreement). Santhera's in‑house legal department represented client(s) Santhera Pharmaceuticals with a team composed by: Oliver P. Kronenberg (Chief Legal Officer), who led the company's in‑house team throughout the matter.

Advisors on Santhera–Nxera Agamree licensing agreement for Japan, South Korea, Australia and New Zealand

Read the full story